supaglutide + metformin

Supaglutide + metformin is a combination therapy consisting of two antidiabetic agents used for the management of type 2 diabetes and potentially for weight loss. Supaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist, similar in class to semaglutide, which stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite. Metformin is a biguanide that decreases hepatic glucose production, increases insulin sensitivity in peripheral tissues, and reduces intestinal absorption of glucose. The combination leverages complementary mechanisms to improve glycemic control more effectively than either agent alone. Both drugs are associated with cardiovascular benefits and may support weight loss when used together.